EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma

Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110158 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Quanqing Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Wuhan Science and Technology Project, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC) is a very common malignant tumor. In the past few decades, platinum-based chemotherapy has been regarded as the standard recommended regimen for patients with metastatic urothelial carcinoma (mUC) who can receive either cisplatin or carboplatin. The emergence of immune checkpoint inhibitors (ICIs) brought some hope for possible treatments for mUC patients who were unfit for platinum therapy. ICIs drugs have emerged as new potential weapons to overcome UC in our lifetime. ICIs block the binding of programmed death-1 (PD-1) to programmed death-ligand 1 (PD-L1), leading to enhancement of the immune function of antitumor T cells. In the treatment of UC, ICIs show an apparent ascendancy and effectively enhance survival rates. With good tolerability and remarkable effects, ICIs have given thousands of patients hope. This article mainly shows the application of PD-1 and PD-L1 inhibitors in mUC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCisplatinB7-H1 Antigen

Stichwörter der Autor:innen

Immune checkpoint inhibitorImmunotherapyMetastatic urothelial carcinomaProgrammed death-1Programmed death-ligand 1

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCisplatinB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China.
  • Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China. Electronic address: lhwhongwei@gdmu.edu.cn.

Förderung

  • Wuhan Science and Technology Project
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Tang, Q., Li, S., Huang, G., & Liu, H. (2023). Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110158

Vancouver

Tang Q, Li S, Huang G, Liu H. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110158

BibTeX
@article{Tang2023,
  author = {Tang, Quanqing and Li, Shihao and Huang, Gaozhen and Liu, Hongwei},
  title = {Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110158}
}
Kostenlos starten →